drugset / Trial / NCT01158521

Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

NCT01158521 ↗

Phase 2 Completed 25 enrolled Case Comprehensive Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works when given before surgery in treating patients with kidney cancer.

Timeline

Start
2010-06
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule — Oral